Colombia

In Colombia, the primary regulatory authority for health products is INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos), which operates under the oversight of the Ministry of Health and Social Protection (Ministerio de Salud y Proteccion Social). The principal legal framework is established by Decree 677 of 1995 for pharmaceuticals, Decree 4725 of 2005 for medical devices and diagnostics, and Resolution 1166 of 2016 for in vitro diagnostics, among other complementary resolutions. All health products marketed in Colombia must obtain a Sanitary Registration (Registro Sanitario) or, in certain cases, a Sanitary Notification (Notificacion Sanitaria), before commercialization. INVIMA classifies medical devices into four risk categories (I, IIA, IIB, and III) following a framework broadly aligned with the Global Harmonization Task Force (GHTF) and the International Medical Device Regulators Forum (IMDRF), while pharmaceuticals undergo review for quality, safety, and efficacy prior to market authorization.

Applicants seeking market authorization in Colombia must appoint a local legal representative or a Colombian-domiciled company to hold the Sanitary Registration, as foreign manufacturers cannot directly obtain or hold registrations. Dossiers generally follow CTD-aligned formats, though INVIMA maintains its own specific submission templates and requirements. Colombia is a member of the Pan American Network for Drug Regulatory Harmonization (PANDRH) and has progressively adopted regional harmonization standards through the Pacific Alliance framework with Chile, Mexico, and Peru, enabling abbreviated review pathways for products already approved by reference stringent regulatory authorities (SRAs) such as the US FDA, EMA, Health Canada, and others. Recent reforms include the implementation of electronic submissions through the INVIMA Virtual Services platform, risk-based review prioritization, and ongoing efforts to streamline timelines under the auspices of improving market access competitiveness in the region.

Public procurement of health products in Colombia operates through a multi-layered system. At the national level, the Ministry of Health and Social Protection sets health policy and benefits package definitions under the General System of Social Security in Health (Sistema General de Seguridad Social en Salud, SGSSS). Procurement is primarily executed through Health Promoting Entities (Entidades Promotoras de Salud, EPS) and public hospital networks, with centralized purchasing for certain strategic products coordinated by the Fondo Colombiano de Enfermedades de Alto Costo (FCEC) and INVIMA-linked mechanisms. Colombia also utilizes the centralized pricing and negotiation mechanism known as the Precio Maximo de Venta (Maximum Sale Price) regime for high-cost medicines, managed by the Comision Nacional de Precios de Medicamentos y Dispositivos Medicos (CNPMDM), which conducts formal price negotiations and can set regulated ceiling prices for products included in the national benefits plan (Plan de Beneficios en Salud, PBS). Subnational entities including departmental health secretariats manage some procurement for public health programs, but the EPS-based model centralizes most purchasing decisions at the insurer level. Public tenders are conducted through the Colombia Compra Eficiente platform (SECOP II), which serves as the national public procurement portal.

The private sector in Colombia constitutes a significant portion of health product consumption, with private hospitals, clinic chains, pharmacy retail networks, and private EPS entities purchasing independently through direct commercial channels and distributor networks. International donor and multilateral procurement channels play a more limited role in Colombia compared to lower-income markets, given the country's upper-middle-income status; however, agencies such as PAHO/WHO, UNICEF, and the Global Fund may support targeted programs in areas such as HIV/AIDS, tuberculosis, and neglected tropical diseases. Colombia does not currently mandate strict local manufacturing preferences as a universal procurement condition, but government policies increasingly incentivize national production capacity through instruments such as tax benefits for local pharmaceutical manufacturers and strategic alliances under the national industrial policy framework. Additionally, Law 1955 of 2019 and related biosimilars regulations have introduced provisions designed to promote competition and reduce costs for biological medicines, reflecting a broader policy orientation toward sustainable public health expenditure.